首頁 > 市場調查報告書 > 醫療設備

病患監測

市場調查報告書

商品編碼

1063167

血液動力學矯正裝置的全球市場(2021年～2028年)

Global Hemodynamic Flow Alteration Devices Market - 2021-2028

出版日期: 2022年03月03日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球血液動力學矯正裝置的市場規模在預測期間(2021年～2028年)中預計將以8.7％的年複合成長率增長。

本報告提供全球血液動力學矯正裝置市場相關調查分析，提供市場動態，產業分析，市場分析，競爭情形等系統性資訊。

簡介
- 市場規模分析，及與前一年同期比較成長分析(%):各終端用戶
- 市場魅力指數:各終端用戶
醫院*
- 簡介
- 市場規模分析，100萬美元(2018年～2028年)，及與前一年同期比較成長分析(%)(2020年～2028年)
診所
門診病人照護中心
居家醫療
其他

第9章全球血液動力學矯正裝置市場:各地區

簡介
- 市場規模分析，100萬美元(2018年～2028年)，及與前一年同期比較成長分析(%)(2020年～2028年):各地區
- 市場魅力指數:各地區
北美
歐洲
南美
亞太地區
中東和非洲

第10章全球血液動力學矯正裝置市場-競爭情形

主要的開發與策略
企業佔有率分析
產品的基準
值得注意的主要企業

第11章全球血液動力學矯正裝置市場-企業簡介概要

Abbott Laboratories*
- 企業概要
- 產品系列及說明
- 主要亮點
- 財務概要
Medtronic
Boston Scientific
Cordis
Contego Medical
Claret Medical
BD
Biosensors International Group Ltd

第12章全球血液動力學矯正裝置市場-DataM

附錄
關於本公司·服務
諮詢方式

簡介目錄

Product Code: DMMD4788

Market Overview

The Global "Hemodynamic Flow Alteration Devices Market"is Expected to reach at a CAGR of 8.7% during the forecast period (2021-2028).

Hemodynamic flow alteration devices are used in treating peripheral vascular diseases which are caused by the formation of atherosclerotic plaques in arteries, which are responsible for the circulation of blood in various organs, the head, and the limbs.

Market Dynamics

Rising prevalence of cardiac disorders and diabetes, rising demand for home-based and non-invasive monitoring systems, advances in technology, increasing funding from private players and government bodies, and an increase in the number of people suffering from hypertension are some of the factors driving the growth of the market.

Increasing R&D investments in the pharmaceuticals and biotechnology industry will drive the market growth

Neurosurgeons and other medical professionals are increasingly interested in therapeutic options that can effectively reduce the risk of fatality or severity of neurovascular diseases in patients. With an increasing number of patients suffering from neurovascular diseases (such as epilepsy, brain stroke, and cerebral aneurysm) and the severity of medical conditions (such as bleeding and local infections) in target patients, demand for effective neurovascular treatments is increasing across key markets such as the United States, Germany, Japan, China, and India. A cerebral aneurysm, for example, is a common neurovascular disorder all over the world. This condition is associated with a significant risk of bleeding or permanent neurological damage. In the United States, there will be 6.5 million brain aneurysm instances documented by 2020; additionally, 30,000 people will have a brain aneurysm rupture each year.

Demand for minimally invasive neurosurgery operations is on the rise. Minimally invasive medical procedures have several advantages over traditional surgical procedures, including a shorter hospital stay, faster patient recovery, increased procedural safety and efficacy, and lower costs. As a result, medical experts worldwide are becoming more accepting of endoscopic and other minimally invasive surgical methods. Geriatric patients are more vulnerable to neurovascular and neurological disorders. They choose treatment options that provide simple diagnosis, simple treatments, increased safety, the shortest possible hospital stay, improved efficacy, and acceptable costs.

Furthermore, aging rises the risk of thrombotic events such as pulmonary embolism, stroke, and epilepsy, all of which can necessitate neurosurgical surgery. Furthermore, arteriovenous malformations can cause hemorrhages and seizures, most common in those over the age of 40. (Source: Medscape). As a result, the growing elderly population and the need for minimally invasive procedures will likely provide considerable growth possibilities for both established and fledgling hemodynamic flow alteration devices companies.

Furthermore, patient awareness about coronary heart diseases and peripheral vascular disorders plays a vital role in market growth. Several educational, government and non-governmental organizations and key players have launched awareness programs to increase awareness about these diseases among patients, doctors, and healthcare providers. The impact of this factor currently influences the market growth in the emerging economies, as the adoption of advanced treatment devices is low in developing nations.

Various governments, particularly those in emerging economies, have boosted their spending on developing their healthcare infrastructure over the last decade. As a result, increased public and private investment in these regions' health infrastructure will boost the adoption of hemodynamic flow alteration devices in developing countries. This contributes to the growth of the global hemodynamic flow alteration devices market.

Risk involved in invasive procedures is likely to hamper the market growth

Apart from the discomfort of invasive monitoring (particularly the insertion of the pulmonary artery catheter), there are several risks associated with this technique, including sepsis, bleeding, cardiac arrhythmias, decreased circulation to the distal limb, bleeding, nerve damage (during insertion), thrombosis, air embolism, and pulmonary capillary necrosis. These factors increase the likelihood of death during invasive hemodynamic procedures. As a result, invasive hemodynamic flow alteration devices is only recommended for a few indications where the risks outweigh the benefits of obtaining the necessary data during the procedure. In addition, invasive hemodynamic flow alteration devices are not recommended for elderly or frail patients. Furthermore, invasive hemodynamic monitoring is prohibitively expensive and necessitates the insertion of catheters into patients by skilled professionals. Although invasive hemodynamic monitoring gives accurate, comprehensive, and continuous data on a patient's hemodynamic state, the above hazards limit its usage. Price regulations, competitive pricing, coverage and payment policies, technical assessments, and comparative effectiveness of therapies are other factors reducing healthcare-related costs. The lengthy regulatory authentication/validation process for developing providers is expected to stifle the growth of hemodynamic flow alteration devices market.

COVID-19 Impact Analysis

COVID-19 pandemic has impacted on every aspect of the medical device industry, including the market for hemodynamic flow alteration devices. Even though emergency and outpatient services are available in cardiology departments, the number of patient visits to hospitals has decreased significantly in the last six months. Patient visits have been significantly reduced due to nationwide lockdowns and social distancing measures. This has resulted in even lower sales of hemodynamic flow alteration devices products.

Segment Analysis

The embolic protection devices segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The hemodynamic flow alteration devices market is divided into embolic protection devices and chronic total occlusion devices. The embolic protection devices segment accounted for most of the hemodynamic flow alteration devices market in 2019. This is due to the advantages of EPDs over CTO devices, such as the ability to capture embolic debris while maintaining continuous blood flow. To prevent distal embolization, embolic protection devices (EPD) trap blood and luminal debris within the saphenous vein graft (SVG) during stenting. These devices are classified into three types: distal occlusion devices, distal filters, and proximal occlusion devices. By capturing and removing debris that may become dislodged during surgical procedures such as SVG interventions, percutaneous coronary intervention, aortic valve stenosis, and so on, these devices provide the most proven strategy for reducing periprocedural myocardial infarction (MI) and major adverse cardiovascular events. EPDs are critical in reducing complications caused by blockages in small blood vessels caused by debris in the bloodstream. They are a component of the most dependable, evidence-based procedure for lowering periprocedural MI and other major cardiovascular events.

The launch of new products are also boosting this segment. For instance, in October 2020, Keystone Heart Ltd., a Venus Medtech Company, received the European CE mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) Device. It is designed and innovated to reduce the risk of cerebral damage by deflecting embolic debris away from the brain. This is done from cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and other surgical transcatheter heart procedures.

Furthermore, Contego Medical, LLC received CE Mark for the new product Vanguard IEPa in April 2017. It is a Peripheral Balloon Angioplasty System with Integrated Embolic Protection. Furthermore, the company intends to market the product to endovascular specialists who perform lower limb angioplasty procedures in Europe. The system represents the most recent advancement in Contego's Integrated Embolic Protection (IEP) technology, incorporating a peripheral angioplasty balloon and a distal embolic filter on the same catheter.

Geographical Analysis

North America region holds the largest market share of global hemodynamic flow alteration devices market

North America is expected to dominate the market in the forecast period. The rising prevalence of cardiovascular and neurovascular diseases in the region is a major factor driving the growth of the embolic protection devices market in the coming years. Obesity prevalence, lifestyle patterns, and unhealthy dietary habits will all have a positive impact on regional market growth. The strong presence of major industry players in North America will fuel the growth of the hemodynamic flow alteration devices industry.

Competitive Landscape

The hemodynamic flow alteration devices market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Medtronic, Boston Scientific, Cordis, Contego Medical, Claret Medical , BD, Biosensors International Group Ltd.

The market for hemodynamic monitoring is fiercely competitive, with several leading companies. Few big firms currently dominate the market in terms of market share. On the other hand, mid-size to smaller businesses are expanding their market presence by releasing new gadgets at lower rates, thanks to technical improvements and product innovations. For instance, in 2020, Cerenovus Stroke Solutions, a suite of three devices designed to assist physicians in clot removal procedures, was launched by Johnson & Johnson. Cerenovus Large Bore Catheter, Cerebase DA Guide Sheath, and Embotrap III Revascularization Device are among the devices.

Key Developments

In 2019, In a feasibility study done in Europe, Innovative Cardiovascular Solutions revealed the first successful clinical use of its next-generation embolic protection device, Emblok, in patients undergoing transcatheter aortic valve implantation (TAVI).

In 2018, Claret Medical, Inc., a major firm known for creating Sentinel, a Cerebral Embolic Protection System, has been acquired by Boston Scientific Corporation.

Abbott Laboratories

Overview: Abbott Laboratories is a healthcare corporation and medical device based in Abbott Park, Illinois, United States. In 1888, Chicago physician Wallace Calvin Abbott created the company to develop well-known pharmaceuticals; now, it distributes medical devices, diagnostics, branded generic medicines, and nutritional supplements. In 2013, it separated its research-based pharmaceuticals business into AbbVie.

Product Portfolio:

Embolished NAV6TM: The Emboshield NAV6TM, Embolic Protection System, is indicated for use as a guidewire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries and atherectomy in lower extremity arteries, either alone or in conjunction with PTA and stenting. The artery diameter at the location of the Filtration Element should be between 2.5 and 7.0 mm.

Why Purchase the Report?

Visualize the composition of the global hemodynamic flow alteration devices market segmentation by type, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global hemodynamic flow alteration devices market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global hemodynamic flow alteration devices market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global hemodynamic flow alteration devices market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Hemodynamic Flow Alteration Devices Market- By Type

Embolic protection devices

Chronic total occlusion devices

Global Hemodynamic Flow Alteration Devices Market- By End User

Hospitals

Clinics

Ambulatory Care Center

Home Care Setting

Others

Global Hemodynamic Flow Alteration Devices Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

1. Global Hemodynamic Flow Alteration Devices Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Global Hemodynamic Flow Alteration Devices Market- Market Definition and Overview

3. Global Hemodynamic Flow Alteration Devices Market- Executive Summary

3.1. Market Snippet by Type
3.2. Market snippet by End User
3.3. Market Snippet by Region

4. Global Hemodynamic Flow Alteration Devices Market- Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing R&D investments in the pharmaceuticals and biotechnology industry.
  - 4.1.1.2. Product approvals
  - 4.1.1.3. Increasing prevalence of diabetes
- 4.1.2. Restraints:
  - 4.1.2.1. Product failure and recalls
  - 4.1.2.2. Postoperative complications
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Global Hemodynamic Flow Alteration Devices Market- Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis

6. Global Hemodynamic Flow Alteration Devices Market- COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. Global Hemodynamic Flow Alteration Devices Market- By Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
- 7.1.2. Market Attractiveness Index, By Type Segment
7.2. Embolic protection devices*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Chronic total occlusion devices

8. Global Hemodynamic Flow Alteration Devices Market- By End User

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User Segment
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Clinics
8.4. Ambulatory Care Center
8.5. Home Care Setting
8.6. Others

9. Global Hemodynamic Flow Alteration Devices Market- By Region

9.1. Introduction
- 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
- 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By End User
- 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. U.K.
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan
  - 9.5.5.4. Australia
  - 9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Global Hemodynamic Flow Alteration Devices Market- Competitive Landscape

10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Product Benchmarking
10.4. Key Companies to Watch

11. Global Hemodynamic Flow Alteration Devices Market- Company Profiles

11.1. Abbott Laboratories*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Medtronic
11.3. Boston Scientific
11.4. Cordis
11.5. Contego Medical
11.6. Claret Medical
11.7. BD
11.8. Biosensors International Group Ltd

LIST NOT EXHAUSTIVE